Market Movers (8-K)
QTZM
Quantumzyme CORPQuantum Genesis AI Corp. has formalized the assignment of a key patent application related to ibuprofen synthesis from its CEO, Naveen Kulkarni, effective retroactively to the application's filing date.
QTZM
Quantumzyme CORPQuantumzyme Corp. has officially changed its name to Quantum Genesis AI Corp. and will trade under the new symbol QGAI effective February 17, 2026.
QTZM
Quantumzyme CORPQuantumzyme Corp. announced its Board and majority shareholders approved a name change to Quantum Genesis AI Corp., pending regulatory filings.
Delay expected
Quarterly Earnings (10-Q)
See all →QTZM
Quantumzyme CORPQuantum Genesis AI Corp. reports a net loss of $24,912 for Q3 2026, with significant operating expenses and a substantial accumulated deficit, raising going concern doubts.
Worse than expected
Capital raise
QTZM
Quantumzyme CORPQuantum Genesis AI Corp. files an amendment to its Form 10-Q for the period ended January 31, 2026, to provide additional disclosure regarding intellectual property and formalize rights acquired via an asset purchase agreement.
Capital raise
Worse than expected
QTZM
Quantumzyme CORPQuantumzyme Corp. files an amendment to its Form 10-Q for the period ended October 31, 2025, to provide additional disclosure on intellectual property and rights formalized from a prior asset purchase agreement.
Capital raise
Worse than expected
QTZM
Quantumzyme CORPQuantum Genesis AI Corp. reported a significant net loss of $4.38 million for the six months ended January 31, 2026, raising substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
QTZM
Quantumzyme CORPQuantumzyme Corp. reported a net loss of $49,868 and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
QTZM
Quantumzyme CORP10-Q: Quantumzyme Corp. Faces Severe Financial Distress Amidst Mounting Losses and Going Concern Doubts
Quantumzyme Corp. reported a significant net loss and a substantial accumulated deficit for the nine months ended April 30, 2025, raising substantial doubt about its ability to continue as a going concern.
Delay expected
Worse than expected
Capital raise
Annual Reports (10-K)
QTZM
Quantumzyme CORPQuantumzyme Corp. files Amendment No. 2 to its 2025 10-K to clarify intellectual property ownership related to its CEO and an enzyme for ibuprofen synthesis.
Capital raise
QTZM
Quantumzyme CORPQuantumzyme Corp. filed an amendment to its annual report, disclosing increased net losses, a significant working capital deficit, and substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
QTZM
Quantumzyme CORPQuantumzyme Corp., an early-stage biotransformation company, reported a net loss of $199,269 for fiscal year 2025 with no revenue, raising substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
Proxy Statements (Def-14A)
QTZM
Quantumzyme CORPQuantumzyme Corp. announces a corporate name change to Quantum Genesis AI Corp., signaling a strategic focus on artificial intelligence.